Tumor FASN expression has been shown to be part of an immune-related signature that informs an immunosuppressive TME characteristic of immune-excluded tumors that may benefit from certain types of immune checkpoint inhibitors (ICIs) [16]. The gene discussed is FASN; the disease is neoplasm.